ScholarLens Back to search
2009•Linchuang gandanbing zazhiRequires access

Clinical observation of adefovir dipivoxil in the treatment of patients with lamivudine-resistant chronic hepatitis B

HU Qin-ming

Open publisher page 0 citations

Abstract

Objective To observe the efficacy and safety of adefovir dipivoxil(ADV) in the treatment of patients with lamivudine-resistant chronic hepatitis B. Methods Eighty-one patients with LAM resistant chronic hepatitis B were randomly divided into ADV(n=41) or LAM(n=40) treatment. 41 patients received ADV and LAM for 12 weeks,and ADV for 36 weeks,and 40 received LAM alone for 48 weeks. Results At 24th and 48th week,the HBV DNA reduction from baseline in ADV-treated patients was significantly greater than in LAM-treated patients;At week 24 and 48,HBeAg negative rate (31.7% and 34.1%),the rate of HBeAg seroconversion (24.4% and 22.0%) and ALT normalization (56.1% and 68.3%) in the ADV group were significantly higher than those in the LAM group. Conclusions ADV is effective and safe for the treatment of chronic hepatitis B patients with LAM resistance.

About this research paper

What this paper is about

Objective To observe the efficacy and safety of adefovir dipivoxil(ADV) in the treatment of patients with lamivudine-resistant chronic hepatitis B. Methods Eighty-one patients with LAM resistant chronic hepatitis B were randomly divided into ADV(n=41) or LAM(n=40) treatment. 41 patients received ADV and LAM for 12 weeks,and ADV for 36 weeks,and 40 received LAM alone for 48 weeks. Results At 24th and 48th week,the HBV DNA reduction from baseline in ADV-treated patients was significantly greater than in LAM-treated patients;At week 24 and 48,HBeAg negative rate (31.7% and 34.1%),the rate of HBeAg seroconversion (24.4% and 22.0%) and ALT normalization (56.1% and 68.3%) in the ADV group were significantly higher than those in the LAM group. Conclusions ADV is effective and safe for the treatment of chronic hepatitis B patients with LAM resistance.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the efficacy and safety of adefovir dipivoxil(ADV) in the treatment of patients with lamivudine-resistant chronic hepatitis B. Methods Eighty-one patients with LAM resistant chronic hepatitis B were randomly divided into ADV(n=41) or LAM(n=40) treatment. 41 patients received ADV and LAM for 12 weeks,and ADV for 36 weeks,and 40 received LAM alone for 48 weeks. Results At 24th and 48th week,the HBV DNA reduction from baseline in ADV-treated patients was significantly greater than in LAM-treated patients;At week 24 and 48,HBeAg negative rate (31.7% and 34.1%),the rate of HBeAg seroconversion (24.4% and 22.0%) and ALT normalization (56.1% and 68.3%) in the ADV group were significantly higher than those in the LAM group. Conclusions ADV is effective and safe for the treatment of chronic hepatitis B patients with LAM resistance.

Key concepts: Adefovir, Medicine, Lamivudine, Chronic hepatitis, Gastroenterology, Internal medicine, Seroconversion, HBeAg

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical observation of adefovir dipivoxil in the treatment of patients with lamivudine-resistant chronic hepatitis B — Research Paper | ScholarLens